2006/8/28 Mylan
Laboratories
Mylan Laboratories to Acquire Up to 71.5% Controlling Interest in
Matrix Laboratories
- Transaction Expected to be Accretive to Mylan in FY '08 -
ジェネリック（後発医薬品）メーカー米２位のマイラン・ラボラトリーズは、インドの製薬会社マトリックス・ラボラトリーズの経営権を最大７億3600万ドル（約860億円）で取得する。アジアと欧州市場への参入を狙う。
Mylan Laboratories
Inc. and Matrix Laboratories Ltd. today announced that Mylan will acquire
up to 71.5% of Matrix shares outstanding for Rs. 306 per Matrix
share. Under the terms of the transaction, Mylan will purchase
51.5% of Matrix's shares outstanding pursuant to an agreement
with certain selling shareholders and will make an "open
offer" to Matrix's remaining shareholders to acquire up to
an additional 20% of Matrix's shares outstanding. Assuming the
open offer is fully subscribed, the total purchase price is
expected to be approximately $736 million. Matrix will remain a
publicly traded company in India and will continue to operate on
an independent basis.
Strategic Rationale
Mylan and Matrix together will have approximately 5,100 employees
in 10 countries. Matrix will provide Mylan with a significant
presence in important emerging pharmaceutical markets, including
India, China, and Africa, as well as a European footprint and
distribution network through Matrix's Docpharma subsidiary. By
combining Matrix's active pharmaceutical ingredient
(API) and
drug development business with Mylan's expertise in finished dosage
forms (FDFs),
this transaction also will allow Mylan to capture incremental
pieces of the value chain through backward vertical integration.
Additionally, Matrix will expand Mylan's capabilities in a number
of key areas including products with higher barriers to entry and
long-term growth opportunities, and allow the company to pursue a
broader portfolio of new products at lower costs. As part of the
Mylan organization, Matrix will benefit from a strong U.S.
presence, expanded production capabilities and manufacturing
capacity, and industry-leading expertise in product development
and process optimization.
Matrix is the world's second largest API player with respect to the number of
drug master files (DMFs), with over 165 APIs in the market or
under development, and 10 API and pharmaceutical intermediate
manufacturing facilities, six of which are FDA approved. Matrix
has diverse API capabilities, knowledge of the API patent
landscape, capability in early API development, a low cost
structure and strong scientific capabilities. Matrix's API
manufacturing platform will provide Mylan with significant cost
savings and enable first in-last out product lifecycles. Their
finished dosage form pipeline will expand Mylan's forms and
therapeutic categories and allow Mylan to pursue a broader
portfolio of product opportunities more economically.
About Mylan
Mylan Laboratories Inc. is a leading pharmaceutical company with
three principal subsidiaries: Mylan Pharmaceuticals Inc., Mylan
Technologies Inc. and UDL Laboratories Inc. Mylan develops,
licenses, manufactures, markets and distributes an extensive line
of generic and proprietary products. For more information about
Mylan, please visit http://www.mylan.com/.
About Matrix
Matrix Laboratories Limited is a public limited company listed on
BSE and NSE, and is engaged in the manufacture of Active
Pharmaceutical Ingredients (APIs) and Solid Oral Dosage Forms.
Matrix is one of the fastest growing API manufacturers in India
and focuses on regulated markets such as U.S. and EU. The company
has a wide range of products in CNS, anti-bacterial, anti-AIDS,
anti-asthmatic, cardiovascular, gastrointestinal, anti-fungal,
pain management and life style related therapeutic segments. Six
API manufacturing facilities of the Matrix Group are approved by
the U.S. FDA. The combined FDA approved capacity of the company
is one of the largest in the country. The company's Finished
Dosage Forms (FDF) manufacturing facility has a capacity to
manufacture 2 billion tablets and 300 million capsules on
two-shift basis. With about 2,300 employees, including over 300
R&D scientists, Matrix focuses on developing APIs with
non-infringing processes to partner with generic players in
regulated markets for their early formulation entry. It has
recently acquired Docpharma, Belgium, for a front-end presence in
Belgium, the Netherlands and Luxembourg. In addition Matrix has a
controlling stake in Mchem (China) and Concord Biotech India.
Newbridge Capital/TPG Ventures, U.S., and Temasek Holdings,
Singapore, are the strategic investors in Matrix with combined
holding of about 40 percent.
Supreme Petrochem
boosting EPS capacity
Supreme Petrochem Ltd. of Mumbai is adding 132 million pounds (60,000t ) of
expandable polystyrene capacity at its Nagothane, India,
styrenics complex.
The project, now under way, will give Supreme its first EPS
capacity at Nagothane. The existing complex already can produce
nearly 600 million pounds(272,000t ) of PS annually.
A business development team also is being readied for EPS
marketing, said Supreme’s senior general manager, Sharad
Parate. The firm is accelerating its expansion into EPS since it
took over control of Chennai, India-based Shin Ho
Petrochemical (India) Ltd.
“We
are already doubling the Chennai plant capacity to 26.5 million
pounds (12,000t ) by this coming March,”
Parate said during
the Society of Plastics Engineers conference, held Dec. 7-8 in
India. He added that Shin Ho’s name changed to SPL Polymers Ltd. after Supreme took charge in
April.
The firm has the ability to double EPS capacity at the Nagothane
plant, based on market demand, he noted.
Overall, Supreme would be investing $225 million by 2011 in
ongoing and planned expansions, which will include more
value-added products, such as ABS.
The expansion also includes increasing PS capacity at Nagothane
to 882 million pounds(400,000t) annually by 2009, according to
Parate, who pointed out that Supreme’s PS resins are exported to 78
countries.
Supreme
Petrochem is a joint venture of Mumbai-based firms Supreme
Industries Ltd. and Rajan Raheja Group. Supreme Industries, established in 1950, claims to be
India’s largest plastics processor, with
18 plants across the country doing injection molding and film,
foam and pipe extrusion. Rajan Raheja is a diversified firm
holding interests in a variety of businesses.
立地 計画 SPL Nagothane PS 272,000t → 400,000t by 2009 EPS （60,000t） 建設中 SPL Polymers
（旧称 Shin Ho Petrochemical）Chennai EPS 6,000t → 12,000t 2007/3
Supreme Petrochem Ltd http://www.supremepetrochem.com/
Supreme Petrochem Ltd (SPL), owns and operates a state-of-the art Polystyrene facility, with an installed capacity of 272,000 TPA located at Nagothane in Raigad District, about 100 Kms south-east of Mumbai city. The facility also includes a world class colouring and compounding facility with an installed capacity of 17,000 TPA.
The Plant is based on technology from the erstwhile Huntsman Chemical Corporation (Now NOVA Chemicals) USA with basic engineering by ABB Lummus Crest, USA.
日本経済新聞夕刊 2007/4/2
経済特区 インド、計画中止続々
反対農民抗議デモ 政府、政策見直し必至
インド政府が主導する経済特区(SEZ)建設計画が厳しい逆風にさらされている。土地収用に抗議した農民と警官隊の衝突で野党や労組などの非難が集中。東部オリッサ州、西ベンガル州の大規模SEZが相次ぎ中止に追い込まれた。首都ニューデリー郊外のハリヤナ州でも新たな抗議デモが起き、中央・州政府は政策の大幅な見直しを迫られる見通しだ。
オリッサ州政府は３月２８日、金属産業の誘致を目指した同州中部カリンガナガールのSEZ計画を無期限に凍結すると発表。西ベンガル州政府も同日、南部ナンディグラムで進めていたSEZの移転を決めた。両SEZの建設に反対した抗議デモでは、いずれも農民らに多数の死傷者が出ている。
外資系企業などが集中するハリヤナ州グルガオン郊外では２８日、大手財閥リライアンスのSEZ予定地に多数の農民が集結し、重機に投石した。同州産業インフラ開発公社は「農民らは既に補償を受けている」と困惑している。
有力経済紙エコノミック・タイムズによると、印政府は印西部ムンバイでSEZを計画中のリライアンスに対し、住民移転問題がこじれそうな土地の取得を中止し開発規模を縮小するよう要請する見通し。
India to complete acetic
acid, acetyl chloride plants by 2008
India's IOL Chemicals
& Pharmaceuticals Ltd. plans to bring online its first
monochloro acetic acid and acetyl chloride plants at Barnala,
Punjab, by June 2008, a company source said Wednesday.
When on-stream, the
plants will have the capacity to produce 6,000 mt/year of
monochloro acetic acid and 5,000 mt/year of acetyl chloride.
IOL recently
boosted its ibuprofen plant capacity to 3,600
mt/year from 1,800 mt/year, and plans to add another 3,600
mt/year
plant by December 2009.
In December 2006,
the company debottlenecked its acetic acid plant
capacity from 30,000 mt/year to 50,000 mt/year, its ethyl acetate
yield from 18,000 mt/year to 33,000 mt/year and acetic anhydride
capacity from 7,500 mt/year to 12,000 mt/year.
IG Petrochemicals considering PA expansion at Taloja
IG
Petrochemicals Ltd is considering expanding its
phthalic anhydride production capacity, the company said Monday.
'The Board of Directors of the Company has considered and
approved the proposed expansion of capacity,' said IG
Petrochemicals in a statement after the board meeting on Monday
evening. The company currently operates 120,000 mt/year
phthalic anhydride plant
at Taloja, near Mumbai.
An IG Petrochemicals official said that the size of the new
capacity would be decided after a feasibility study and would be
added in the second half of 2008.
IG Petrochemicals had previously increased its production
phthalic anhydride from 45,000 mt/year to 120,000 mt/year at Talo
Incorporated in the year 1988 as 100% Export Oriented Unit (EOU), I G Petrochemicals Limited has relentlessly marched towards achieving its goals and objectives.
Our principal business revolves around the production of Phthalic Anhydride, which is mainly used in the manufacture of Plasticizers for production of PVC products, shoe soles and other commodities, Alkyd Resins for manufacturing of paints, as an intermediate in production of dyes and pigments, and in production of Unsaturated Polyester Resins (UPRs).
The plant is located at MIDC, Taloja in Raigad District, Maharashtra, India, 50 Km away from Jawaharlal Nehru Port Trust (JNPT), Nhavasheva.
Indian SAPL-IFC in talks on loan for Egypt's PET resin project
India's South Asian
Petrochem Ltd. is in talks with the International Finance Corp.
on the sale of an equity stake and a loan for development of a 315,000 mt/year
polyethylene terephthalate resin plant at Damietta on Egypt's
Mediterranean coast, a company official said Tuesday.
(IFC がエジプト計画のためにSAPLに融資を行い、同社の株式を購入する）
The
Kolkata-based SAPL early this year entered into a joint venture
agreement with Egyptian Petrochemical Holding Co. to set up a PET resin plant at
Damietta by the end of 2009. SAPL will hold 70% equity in the
project, while Echem and Engineering for the Petroleum &
Process Industries will own 23% and 7%, respectively.
The project, the first PET plant in North Africa, will export to
Europe and North Africa, besides catering to the Egyptian market.
SAPL, India's second-largest PET manufacturer, operates a 180,000 mt/year
Bottle Grade PET resin plant at Haldia in West Bengal,
close to the Mitsubishi's PTA plant.
国際金融公社(IFC)
開発途上国で民間セクターへの投融資を持続可能な形で促進し、貧困削減と人々の生活水準の向上に役立つこと、それがIFCの使命です。http://www.ifc.org/ifcext/spiwebsite1.nsf/0/6f58a8630c470efb8525736b0074fe64?OpenDocument
South Asian Petrochem Limited (SAPL or the sponsor), India's second largest manufacturer of Polyethylene Terephthalate (PET), is planning to set up a joint venture with the Egyptian Petrochemical Holding Company (Echem), an agency of the Government of Egypt (GoE), to establish a 315,000 tons per annum (tpa) greenfield PET resin plant in Damietta, on Egypt's Mediterranean coast. SAPL will have a 70% share in Egyptian Indian Polyester Co. (EIPET or the project company) whereas Echem will hold 23% and Engineering for the Petroleum & Process Industries (Enppi) will hold the balance 7%. The project has an estimated cost of approximately $135 million (including working capital requirements).
PET, which is produced from mono ethylene glycol (MEG) and terephthalic acid (PTA), is sold in small pellets and its major use is for the manufacture of lightweight plastic bottles for carbonated soft drinks and water. The project's output is expected to be exported to Europe and the United States and also sold in Egypt, Middle East and North Africa.
The project will be the first PET plant in North Africa. Egypt has significant advantages for the location of a PET plant including:
- low logistics costs for sales to the European Union (EU) and North American markets;
- access to the fast growing and underserved African and Middle Eastern markets;
- excellent port/infrastructure facilities;
- favorable trade agreements with the EU; and
- proximity to sources of MEG feedstock.
Tata Chemicals acquires 100-per cent stake in General Chemical Industrial Products Inc, USA
Tata Chemicals (TCL), part of the Tata Group, has entered into definitive agreements to acquire the soda ash business of General Chemical Industrial Products Inc (GCIP), a US based chemical company, for US$1,005 million. Harbinger Capital Partners is GCIP's majority shareholder. The transaction is subject to shareholder and regulatory approvals.
GCIP's subsidiary, General Chemical (soda ash) Partners (GCSAP), is a significant soda ash producer in the US with a capacity of 2.5 million tpa of natural soda ash. GCSAP has mining and manufacturing facilities located at Green River Basin in Wyoming, USA, which provides it access to the world's largest and most economically recoverable trona ore deposits that is then converted into soda ash.
The acquisition of GCIP will lead to a sizeable increase in TCL's global soda ash capacity making it one of the largest soda ash producers worldwide. Over 50 per cent of this capacity will be from the natural route, which is a significantly more economical route of producing soda ash than the synthetic route and is a natural hedge against the commodity cycle. This acquisition, together with its other global soda ash facilities, will give TCL a unique market position.
The merger will provide TCL access
to markets in North America, Latin America and the Far East,
which complement its existing markets.
A. Schulman announces plans to establish a masterbatch facility in India
A. Schulman, Inc.
announced today it plans to establish a masterbatch facility in
western India to better serve its customers in the region, which
is a key geographic growth market for A. Schulman. A specific
location for the facility has not yet been determined.
The facility
initially will consist of one line and will manufacture the
Company’s masterbatch products which serve
the packaging, appliance and consumer products markets. Its
capacity is projected to be approximately 12 million pounds
per year,
and production is expected to begin within the next 12 months.
“In line with our
strategic direction, we are continuing our geographic expansion
in growing markets across Asia,” said Joseph M. Gingo, Chairman,
President and Chief Executive Officer.
“The new plant,
which will be our third manufacturing facility in Asia, will
increase our capability to serve our growing customer base in
this attractive market and will be another step in our progress
toward becoming the number-one global manufacturer in the
masterbatch market.”